Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT327 + carboplatin + paclitaxel
- Development stage
- Phase 3
- Lead developer
- BioNTech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BNT327 + carboplatin + paclitaxel is a combination regimen used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). BNT327 is an investigational bispecific antibody targeting both PD-L1 and VEGF-A. By simultaneously inhibiting PD-L1 and VEGF-A, BNT327 restores cytotoxic T cell functionality and inhibits tumor angiogenesis and immune evasion. Carboplatin and paclitaxel are standard chemotherapy agents: carboplatin is a platinum-based DNA crosslinker causing apoptosis, and paclitaxel is a taxane that stabilizes microtubules, thereby arresting cells in mitosis and promoting cell death. This combination aims to synergistically target tumor growth and survival by immune reactivation, inhibition of angiogenesis, and direct cytotoxicity[1][4][6][8].
- Other names
- PM8002PM-8002PM 8002paclitaxelcarboplatin
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on BNT327 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT327 + carboplatin + paclitaxel.